About Us
A leading independent service provider to the global pharma, medical technology companies, and emerging clients for the development of inhalation formulation.
Respiratory Development Backed by Science
i2c Pharmaceutical Services is a leading independent service provider based in Cardiff, Wales. Built on strong scientific expertise and years of respiratory development experience, we support pharmaceutical, medical technology, and emerging companies working in inhalation. Our work covers inhalation formulation development, and the practical steps needed to move programmes forward.
From early formulation work to advanced analytical and gamma scintigraphy, our integrated facilities support programmes from concept through clinical development. This connected approach helps generate reliable data, guide decision-making, and reduce complexity across the development pathway.
Mission
To deliver high-quality, independent research and development services for inhalation formulation, supporting global pharmaceutical and medtech clients from concept to clinic with expertise, integrity, and efficiency.
Vision
To be the trusted partner of choice for innovative inhalation drug development, advancing respiratory health through scientific excellence and client-focused solutions.
Board of Directors
Andrew Brown, PhD
Chief Executive Officer30 years of experience in product and device development, formerly at GSK, Oriel, and OBG.
John Pritchard, PhD
ChairmanSpecialist in inhalation R&D and respiratory product launch, with experience at GSK, 3M, and Philips Healthcare.
Prof. Glyn Taylor, PhD
CSO & Founding Director40 years in inhalation product development and clinical PK studies at Cardiff University and i2c.
Simon Warren, PhD
Research Director30 years in formulation development and clinical imaging of inhalation products at i2c.
Rhodri Turner, PhD
Non-Executive Director15 years in research commercialisation and technology transfer at Cardiff University.
Sustainability in Inhalation
The inhalation sector is under growing pressure to reduce environmental impact, especially as conventional propellants face increasing scrutiny for their high global warming potential. The challenge is not only to move toward greener alternatives, but to do so without compromising product performance, quality, or reliability.
Today, lower GWP propellants and smarter formulation approaches are shaping the future of inhalation development. The focus is shifting toward solutions that support both technical excellence and long-term sustainability.
Proprietary technology for a lower impact future
Let’s transform inhalation development with smarter solutions designed for performance, progress, and a healthier tomorrow.